{"filings":[{"id":40446,"accession_number":"0001213900-26-055070","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2026-05-12T20:10:33+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD Q1 2026 net income $103K, license revenue up 84% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income from continuing operations of $103K vs net loss of $636K in Q1 2025.","License revenue $724K, up 84% YoY, primarily from Mayne License Agreement.","Total operating expenses $1.45M, down 13.6% from $1.67M in prior year.","Cash and cash equivalents $8.4M as of March 31, 2026.","Company continues to evaluate strategic alternatives including M&A or sale of assets."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":724000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112976,"accession_number":"0001213900-26-036519","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD reports 2025 full-year net loss of $0.7M, license revenue up 71.6% to $3.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations narrowed to $0.7M ($0.06 per share) from $2.3M in 2024.","License revenue rose 71.6% to $3.0M, primarily driven by the Mayne License Agreement.","Total operating expenses decreased 5.9% to $7.4M, partly due to lower impairment charges.","Cash and cash equivalents stood at $7.5M as of December 31, 2025.","Company continues to evaluate strategic alternatives including M&A or sale of assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112975,"accession_number":"0001213900-26-005779","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"TherapeuticsMD appoints CRI as new auditor; prior reports included going concern emphasis","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit Committee approved CRI as independent auditor effective Jan 15, 2026; BPB dismissed.","Change due to CRI acquiring certain assets of BPB's capital markets practice.","No disagreements or reportable events with BPB during fiscal 2025 and 2024.","BPB's reports for FY 2024 and 2023 included an explanatory paragraph on going concern uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129375,"accession_number":"0001213900-25-122240","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TherapeuticsMD shareholders approve all proposals including share authorization increase to 640M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four director nominees elected: Thompson, Collins, Naughton, Roberts; each received >5.1M for votes.","Advisory say-on-pay approved: 5.16M for, 81.6K against, 8.3K abstain.","Advisory vote on frequency: 1-year chosen (5.18M votes); board adopts annual advisory vote.","Ratification of Berkowitz Pollack Brant as FY2025 auditor approved: 6.77M for, 42.2K against.","Amendment to increase authorized common shares to 640M approved: 6.27M for, 548.9K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129374,"accession_number":"0001213900-25-109479","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD posts Q3 net income of $50K vs year-ago loss; license revenue up 43%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income from continuing operations was $50K ($0.00 per share) vs net loss of $567K ($0.05) in Q3 2024.","License revenue from Mayne Agreement rose 43% to $784K from $547K year-over-year.","Total operating expenses decreased 2.1% to $1,646K, roughly flat from prior year.","Company evaluating strategic alternatives including M&A, sale of assets; no timetable set.","Cash and cash equivalents stood at $7.1 million as of September 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":2129000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145944,"accession_number":"0001213900-25-074975","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD Q2 net income $545K vs loss last year; license revenue up to $1.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income from continuing operations $545K ($0.05/share) vs net loss of -$1.05M (-$0.09) in Q2 2024.","License revenue $1.0M, up $0.7M from $234K, driven by changes in Mayne License Agreement product sales.","Total operating expenses fell 45.5% to $1.647M, primarily due to no impairment in current quarter.","Cash and equivalents $6.1M as of June 30, 2025; company continues strategic alternatives review.","No timetable set for strategic transaction outcome; no assurance of any deal."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1345000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164239,"accession_number":"0001213900-25-042663","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD Q1 net loss narrows to $636K; license revenue up 26%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $(636)K ($0.06/sh) vs $(809)K ($0.07/sh) in Q1 2024.","License revenue $393K, up 25.8% from $313K, driven by Mayne License sales changes.","Operating expenses $1,264K, down 13.1% from prior year on royalty business efficiencies.","Cash and equivalents $5.7M at March 31, 2025; no debt disclosed.","Company continues evaluating strategic alternatives including M&A or asset sale."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":393000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164238,"accession_number":"0001213900-25-030089","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"TherapeuticsMD files lawsuit against Mayne Pharma for breach of contract over 2022 agreements","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed April 8, 2025 in U.S. District Court for Delaware (Case No. not assigned).","Seeks damages for breach of contract, implied covenant, fraudulent inducement, and unjust enrichment.","Dispute centers on net working capital allowances under License and Transaction Agreements dated December 4, 2022.","No specified damages amount; litigation outcome uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182012,"accession_number":"0001013762-25-003407","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD reports FY2024 net loss narrowed to $2.3M; license revenue up 35%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations $(2.3)M, or $(0.20)/share, improved from $(7.7)M loss in 2023.","License revenue $1.8M, up 35.3% YoY, driven by changes in sales of Mayne licensed products.","Total operating expenses $6.5M, down 33.6% from $9.8M, due to cost cuts and transition to royalty model.","Cash and cash equivalents $5.1M as of December 31, 2024.","Company continues to evaluate strategic alternatives including M&A, sale of assets, or other transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198673,"accession_number":"0001213900-24-106095","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TherapeuticsMD annual meeting votes: all director nominees elected, say-on-pay approved, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four board nominees elected: Thompson 4.60M for, Collins 4.73M, Naughton 4.64M, Roberts 4.63M; broker non-votes 1.97M each.","Non-binding advisory vote on 2023 exec comp: 4.61M for, 218K against, 30K abstain; broker non-votes 1.97M.","Ratification of Berkowitz Pollack Brant as auditor for FY2024: 6.44M for, 383K against, 12K abstain; no broker non-votes.","Meeting held Dec 5, 2024; quorum of 6.83M shares (59.2% of 11.53M outstanding shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198672,"accession_number":"0001213900-24-096804","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD narrows Q3 net loss to $567K; license revenue rises to $547K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations of $567K ($0.05 per share) vs. $1.4M loss ($0.13) in Q3 2023.","License revenue from Mayne agreement totaled $547K, up from negative $53K in Q3 2023.","Total operating expenses fell 18.3% YoY to $1.4M on cost reductions after royalty transition.","Cash and equivalents stood at $5.0M as of Sept 30, 2024.","Company continues to evaluate strategic alternatives including M&A or asset sale; no timeline set."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1094000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214699,"accession_number":"0001213900-24-080719","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"TherapeuticsMD sets 2024 annual meeting for Dec 5; proxy deadlines Sep 30","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Annual Meeting scheduled for December 5, 2024; record date October 17, 2024.","Stockholder proposals for inclusion in proxy materials (Rule 14a-8) must be received by September 30, 2024.","Director nominations and other proposals must also be submitted by close of business September 30, 2024.","Meeting is more than 30 days after anniversary of 2023 meeting, triggering revised deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214698,"accession_number":"0001213900-24-067670","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD Q2 net loss narrows to $1.05M; evaluating strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations $1.05M ($0.09/sh) vs $2.4M ($0.24/sh) in Q2 2023.","License revenue from Mayne License Agreement fell 46.5% to $234K from $437K.","Operating expenses decreased 8.1% to $2.7M; cash and equivalents $5.2M as of June 30.","Company continues to evaluate strategic alternatives including M&A or asset sale; no assurance of outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":547000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233835,"accession_number":"0001213900-24-041735","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD Q1 net loss narrows to $0.8M; strategic alternatives review ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations of $0.8M ($0.07/share) vs. $2.3M ($0.24/share) in Q1 2023.","Gross license royalties of $1.2M under Mayne License Agreement; net royalties: $0.3M revenue and $0.3M other income.","Operating expenses down 52.8% to $1.5M from $3.1M, driven by transition to royalty-based model.","Cash and equivalents $4.3M at Mar 31, 2024; continues evaluating strategic alternatives including M&A or sale."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":313000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251817,"accession_number":"0001213900-24-027998","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD full-year 2023 net loss $7.7M, cash $4.3M; strategic review ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations $(7.7)M ($(0.74) per share) vs $1.1M income ($0.12) in 2022.","Gross license royalties $4.5M under Mayne License; net recognized $1.3M revenue and $0.5M other income.","Operating expenses fell 85.4% to $9.8M, reflecting transition from commercial pharma to royalty model.","Cash and equivalents $4.3M at Dec 31, 2023; company continues exploring strategic alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269349,"accession_number":"0001193125-23-277136","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD reports Q3 net loss $1.4M; evaluates strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $1.4M ($0.13/share) vs $14.6M ($1.58) in Q3 2022.","License and service revenue negative $0.1M; gross royalties $1.2M for quarter.","Operating expenses fell 88.2% to $1.7M on transition to royalty-based model.","Board evaluating strategic alternatives including M&A, sale, or other transaction."],"consensus_eps_estimate":-0.051,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":800000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286330,"accession_number":"0001193125-23-216056","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["1.01","5.02"],"status":"ready","headline":"TherapeuticsMD appoints Joseph Ziegler as Principal Financial Officer after resignation of Michael Donegan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Entered Master Services Agreement with JZ Advisory Group for $10,000/month plus 7,500 restricted stock units for Joseph Ziegler as Principal Financial Officer","Michael Donegan resigned as Principal Financial and Accounting Officer effective August 17, 2023","Joseph Ziegler, founder of JZ Advisory Group, succeeded Donegan; previously CFO at DAS Health and Encompass Onsite","Agreement has a three-year term with automatic renewal unless either party provides 30-day non-extension notice"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286329,"accession_number":"0001193125-23-211446","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD Q2 net loss narrows to $2.4M as royalty transition continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops of $2.4M ($0.24 per share) vs $14.9M ($1.70) in Q2 2022.","License and service revenue rose to $0.4M from $0.3M year-over-year, driven by Mayne License Agreement.","Total operating expenses fell 80.4% to $2.9M reflecting wind-down of manufacturing and commercial ops.","CEO says company is focused on cost reduction and cash conservation during ongoing business transformation."],"consensus_eps_estimate":-0.0714,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":853000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286328,"accession_number":"0001193125-23-184765","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"TherapeuticsMD dismisses Grant Thornton, engages BPB; prior reports had going concern note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant Thornton dismissed as independent auditor on July 7, 2023; Berkowitz Pollack Brant appointed.","GT's reports for FY 2022 and 2021 included an explanatory paragraph on going concern uncertainty.","No disagreements with GT on accounting principles or audit scope; no reportable events occurred.","Audit change resulted from a request for proposal process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286327,"accession_number":"0001193125-23-182808","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"TherapeuticsMD issues 312,525 shares to Rubric Capital for $1.15M; amends bylaws","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 312,525 shares at $3.6797/share to Rubric Capital Management on June 29, 2023, gross proceeds $1,149,998.","Stockholders approved the Subscription Agreement at the June 26, 2023 annual meeting under Nasdaq rules.","Board amended bylaws to exempt the Rubric Capital deal from Nevada control share acquisition statutes.","Shares sold in private placement exempt from registration under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306169,"accession_number":"0001193125-23-176709","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TherapeuticsMD stockholders approve charter amendment and private placement at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected all four director nominees (Thompson, Collins, Naughton, Roberts) with over 4 million 'for' votes each.","Approved charter amendment to increase authorized common shares from 12 million to 32 million with 5,431,781 votes for.","Approved private placement of up to 5 million shares to Rubric Capital Management with 4,178,998 votes for.","Non-binding advisory vote on named executive officer compensation passed with 4,007,930 votes for.","Ratified Grant Thornton LLP as independent auditor for fiscal 2023 with 5,875,689 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306168,"accession_number":"0001193125-23-145019","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD Q1 net loss narrows to $2.3M from $17.9M; continuing ops loss $0.24/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations $2.3M ($0.24/share) vs $17.9M ($2.08) in Q1 2022.","License and service revenues $0.4M, down from $0.7M due to transition to royalty-based business.","Total operating expenses fell 82.8% to $3.1M, reflecting business transformation and reduced infrastructure.","Net loss from discontinued ops $1.3M ($0.13/share) vs $31.1M ($3.62), as wind-down continues."],"consensus_eps_estimate":0.0612,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":416000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306167,"accession_number":"0001193125-23-137263","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"TherapeuticsMD enters $5M private placement with Rubric Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement to sell up to 5M shares at volume-weighted average price, aggregate up to $5M.","Initial drawdown of 312,525 shares at $3.6797/share upon stockholder approval.","Stockholders must approve the private placement at the upcoming annual meeting.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306166,"accession_number":"0001193125-23-110686","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-04-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"TherapeuticsMD sets combined 2022/2023 annual meeting for June 19, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting set for June 19, 2023; record date April 20, 2023 (past).","Company did not hold a 2022 annual meeting; 2022 and 2023 meetings combined.","Deadline for Rule 14a-8 shareholder proposals is May 1, 2023.","Deadline for director nominations and universal proxy notices also May 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306165,"accession_number":"0001193125-23-095317","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-04-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD posts $1.1M net income from continuing ops in FY2022 vs loss of $79.3M in 2021","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["License revenue surged to $70.0M from $2.6M, driven by $140M upfront from Mayne Pharma transaction.","Company repaid all $188.3M debt, redeemed Series A preferred stock, and has $38.1M cash on hand.","Discontinued ops generated $80.7M product revenue; net income of $110.9M vs loss in 2021.","Reduced to one full-time employee; transition to virtual royalty model from Mayne Pharma license.","Eligible for up to $30M milestones and 7.5%-8% royalties for 20 years with $3M minimum annual royalties."],"consensus_eps_estimate":0.0612,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":416000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325354,"accession_number":"0001193125-23-050813","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"TherapeuticsMD amends CEO Walker's employment; enters consulting agreement with former CFO Donegan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Walker's base salary increased to $500k after Apr 15, 2023; receives $20,909 lump-sum bonus and 70,000 RSUs.","Enhanced severance: 18 months salary, 1.5x target bonus, 24 months COBRA, full equity vesting on termination without cause or for good reason.","Former interim CFO Donegan to provide consulting services as PFO/PAO via MCD Consulting; receives $100k signing fee, $50k/month, and 50,000 RSUs.","Consulting agreement anticipated to end March 31, 2023; if extended, hourly rate $205.28; additional $100k fee on termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325353,"accession_number":"0001193125-23-010258","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-01-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TherapeuticsMD terminates employment agreement of CFO Michael Donegan; remains as consulting CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Michael Donegan's employment agreement terminated without 'Good Cause' effective Dec 30, 2022.","Separation benefits: 12-month base salary, 2022 target bonus, 24 months COBRA, full equity vesting.","Eligible for $135k in performance bonuses under 2022 ERB-Plan, including $67.5k for transition assistance.","Donegan continues as Principal Financial Officer and Principal Accounting Officer in consulting capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325352,"accession_number":"0001193125-23-007281","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"TXMD receives Nasdaq deficiency notice for missing annual meeting; has 45 days to submit compliance plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Jan 6, 2023 for failing to hold 2022 annual meeting within 12 months of FYE Dec 31, 2021.","No immediate effect on listing; TXMD has until Feb 20, 2023 to submit a plan to regain compliance.","If plan accepted, Nasdaq may grant extension until June 29, 2023 to hold annual meeting.","Company intends to submit a plan and hold the 2022 annual meeting before June 29, 2023.","If plan rejected, TXMD can appeal to a Hearings Panel; listing would remain pending decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325350,"accession_number":"0001193125-23-003686","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K/A","filed_at":"2023-01-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"TherapeuticsMD closes Mayne Pharma license deal, appoints new CEO, reports pro forma loss","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On Dec 30, 2022, terminated co-CEOs Brian Bernick and Mark Glickman; Glickman eligible for $100k consulting fee plus performance bonuses.","On Jan 4, 2023, appointed General Counsel Marlan Walker as CEO and Principal Executive Officer.","Mayne Pharma paid $140M upfront for licenses and assets; plus ~$12.1M for working capital and $1M prepaid royalties.","Pro forma 2021 net loss of $7.0M, 9mo 2022 net loss of $6.6M; balance sheet shows debt eliminated, cash of ~$128M post-transaction.","Royalty stream includes 8% on first $80M annual sales, minimum $3M/year for 12 years, and milestone payments up to $30M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325351,"accession_number":"0001193125-23-000222","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["1.01","1.02","2.01","5.02","7.01","8.01","9.01"],"status":"ready","headline":"TherapeuticsMD closes transaction with Mayne Pharma; receives $153M upfront, pays down debt and redeems preferred stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total upfront cash of ~$153.1M ($140M license/sale + $13.1M for working capital and prepaid royalties).","Eligible for up to $30M in sales milestones and royalties of 7.5%–8% on net sales for 20 years (minimum $3M/yr for 12 years).","Proceeds used to repay all debt under Sixth Street facility and redeem all 29,000 Series A Preferred shares at $1,333 each.","Directors Bisaro, Ling, Musing, Russell resigned; Marlan Walker appointed Principal Executive Officer.","Paid ~$3M make-whole to Rubric Capital Management affiliates per subscription agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343119,"accession_number":"0001193125-22-298002","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD licenses products to Mayne Pharma for ~$153.1M upfront plus royalties and milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $140.0M plus ~$13.1M for net working capital at closing.","Min annual royalty $3M/year for 12 years (cumulative ~$42.6M); plus sales milestones up to $30M.","Royalty rate 8% on first $80M annual net sales, 7.5% above $80M over 20 years.","Proceeds will repay Sixth Street debt and redeem preferred equity; TXMD to become a royalty company.","Closing expected end of 2022, subject to HSR waiting period; no financing condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343118,"accession_number":"0001193125-22-296035","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"TherapeuticsMD extends debt maturity to Dec 31, 2022; pays $4.2M accrued interest and $750K fee","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 17 extends Financing Agreement maturity to Dec 31, 2022, contingent on certain milestones.","Minimum cash covenant set at $7.5M; amendment fee of $750,000 paid to lenders.","Company paid approximately $4.2M in accrued and unpaid interest as of Nov 30, 2022.","Board continues evaluating options to strengthen capital structure and maintain normal operations.","Company faces going-concern risk if it cannot refinance or raise additional capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343117,"accession_number":"0001564590-22-037633","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD Q3 revenue $20.9M, net loss $29.0M; cash drops to $27.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $20.9M, down 18% YoY; net loss $29.0M ($3.13/sh) vs $47.4M loss YoY.","Operating expenses cut $22.2M YoY to $37.9M; product gross margin 82% vs 78%.","ANNOVERA revenue $10.4M (-$1.4M YoY), Rx up 10% YoY; IMVEXXY $6.9M; BIJUVA $2.7M.","Cash $27.1M at Sep 30, down from $65.1M at Dec 31; post-quarter $7M investment from Rubric Capital.","Net debt and preferred stock liability $117.1M; no earnings call due to strategic alternatives review."],"consensus_eps_estimate":null,"consensus_eps_actual":3.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":68811000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343116,"accession_number":"0001193125-22-273110","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD raises $7M from Rubric Capital; extends debt maturity to Nov 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 7,000 shares of Series A Preferred Stock to Rubric Capital Management for $7M gross proceeds.","Net proceeds to be used for working capital and general corporate purposes.","Financing agreement maturity extended to Nov 30, 2022; lenders received warrants for 125k shares at $0.01.","Warrants have a 10-year term and are exercisable via cashless exercise.","Board and management continue to assess strategic alternatives to strengthen long-term financial position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343115,"accession_number":"0001193125-22-256102","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD raises $7M via Series A Preferred from Rubric Capital, extends debt maturity to Oct 31","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 7,000 Series A Preferred shares to Rubric Capital Management for $7M gross proceeds; proceeds for working capital.","Financing agreement maturity extended to Oct 31, 2022; further extension to Nov 30 possible with additional $7M equity raise.","Issued warrants to Sixth Street lenders for 125,000 common shares at $0.01 exercise price, expiring Sep 30, 2032.","Company continues strategic alternatives process to strengthen long-term financial position.","Securities issued in private placement under Section 4(a)(2) and Regulation D; no registration rights granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359671,"accession_number":"0001193125-22-242398","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD CEO departs; co-founder & CBO named interim co-CEOs; strategic review ongoing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Hugh O'Dowd departed Sept 6, 2022; termination without 'Good Cause' triggers severance.","Dr. Brian Bernick (co-founder, Chief Scientific/Medical Officer) and Mark Glickman (Chief Business Officer) named Interim Co-CEOs.","Tommy Thompson, former Chairman since 2012, appointed Executive Chairman.","Press release states the Company continues its robust strategic alternatives process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359670,"accession_number":"0001193125-22-232894","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-08-29T23:59:59+00:00","items":["5.02","1.01"],"status":"ready","headline":"TherapeuticsMD appoints Rubric Capital partner Justin Roberts to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin Roberts, Partner at Rubric Capital Management, appointed to fill newly created Board seat effective Aug. 23, 2022.","Board size increased to nine directors; Roberts will stand for election at 2022 Annual Meeting.","Rubric recently invested $15M in TherapeuticsMD via private placement of Series A Preferred and common stock (July 29, 2022).","Roberts has elected not to receive any director compensation at this time.","No other arrangements or material transactions between Roberts and Company beyond the Rubric investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359669,"accession_number":"0001564590-22-029394","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD Q2 net income $112.3M; revenue $28.6M (+24% YoY); ANNOVERA sales double","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $28.6M, up 24% YoY; net income $112.3M ($12.83 basic EPS) vs net loss $42.7M in Q2 2021.","ANNOVERA revenue $18.3M, up 91% YoY; 9,329 TRx (+28% YoY); over 13,000 prescribing HCPs (+65%).","Operating expenses fell 21% to $42.7M; debt reduced to $90.8M after repaying $125M in 2022.","Cash $26.3M plus $11.3M restricted; vitaCare divestiture gain $143.4M.","FDA approved sNDA for ANNOVERA; CEO highlights focus on women's health."],"consensus_eps_estimate":null,"consensus_eps_actual":7.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":47894000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359668,"accession_number":"0001193125-22-207645","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD raises $15M from Rubric, extends debt maturity to Sept 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 15,000 Series A Preferred ($1,000 stated value) and 565,000 common shares to Rubric for $15M gross proceeds.","Rubric owns ~18.3% of common stock post-closing; Series A has $1,333/share liquidation preference and matures Dec 31, 2022.","Financing Agreement with Sixth Street extended to Sept 30, 2022; can extend to Nov 30 if $7M additional equity raised.","Sixth Street received warrants to buy up to 200,000 common shares at $0.01, plus 125,000 per monthly extension.","Proceeds used for working capital and general corporate purposes; Board evaluating strategic alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359667,"accession_number":"0001193125-22-205794","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"TherapeuticsMD extends loan maturity to July 29, 2022; evaluating Chapter 11 protection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maturity date of Financing Agreement amended to July 29, 2022, a one-day extension from the amendment date.","Company's board evaluating all options for capital structure, including refinancing and potential Chapter 11 filing.","Company states it intends to maintain normal operations during evaluation.","Amendment indicates near-term liquidity stress and risk of bankruptcy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359666,"accession_number":"0001193125-22-204332","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TherapeuticsMD extends loan maturity by one day, evaluating Chapter 11 filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended maturity of Financing Agreement from July 27 to July 28, 2022.","Evaluating strategic alternatives including potential refinancing or Chapter 11 protection.","Intends to maintain normal operations during evaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359665,"accession_number":"0001193125-22-200476","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"TherapeuticsMD extends loan maturity to July 27, appoints CRO, explores Chapter 11","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 13 extends Financing Agreement maturity to July 27, 2022.","Company pays Lenders $2.9 million interest payment as part of amendment.","Jeffrey Varsalone of G2 Capital Advisors appointed as Chief Restructuring Officer.","Board evaluating all options including refinancing, strategic alternatives, and Chapter 11.","Company intends to maintain normal operations while evaluating options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359664,"accession_number":"0001193125-22-193376","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-07-14T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"TherapeuticsMD terminates Merger Agreement; debt maturity extended to July 24; evaluating Chapter 11","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tender offer at $10/share expired July 12 without acquiring required majority; Merger Agreement terminated July 13.","Debt maturity under Financing Agreement extended to July 24, 2022; Company paid $1.2M paid-in-kind amendment fee.","Board evaluating all options including potential refinancing and Chapter 11 filing; normal operations continue during evaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378479,"accession_number":"0001564590-22-022527","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K/A","filed_at":"2022-06-06T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"TherapeuticsMD adopts bylaw amendment facilitating acquisition by Athene Parent via tender offer and merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Bylaw amendment adopted May 27, 2022, makes Nevada control share statutes inapplicable to the merger agreement with Athene Parent and Merger Sub.","Amendment enables cash tender offer for all outstanding TXMD common stock and subsequent merger.","This 8-K/A corrects item number from 1.01 to 5.03; no disclosure changes from the original June 3, 2022 filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378487,"accession_number":"0001564590-22-022465","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"TherapeuticsMD signs merger agreement with Athene Parent for cash tender offer and merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger Agreement dated May 27, 2022 with Athene Parent, Inc. and Athene Merger Sub, Inc.","Cash tender offer to acquire all outstanding TXMD common shares, followed by a merger.","Board amended bylaws to exempt the transaction from Nevada's control share acquisition statute.","No deal price, premium, or expected closing date disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378486,"accession_number":"0001564590-22-021755","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-05-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TherapeuticsMD to be acquired by EW Healthcare Partners for $10.00/share in all-cash deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Offer price of $10.00 per share represents 367.3% premium over May 27 closing price.","Total enterprise value approx. $177 million; tender offer to commence by June 6, 2022.","Board unanimously approved; no stockholder vote required under Nevada law.","Financing: $93M equity commitment from EW; Sixth Street debt amended with interest pause and maturity extended to July 13, 2022.","If merger fails to close by July 13, 2022, events of default under financing agreement could impact going concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378485,"accession_number":"0001564590-22-020824","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves TherapeuticsMD's ANNOVERA sNDA, boosting supply by ~7,000 rings","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved sNDA for ANNOVERA with revised in vitro release testing specification to allow normal manufacturing variability.","Company expects ~7,000 additional rings to enter supply chain in Q2/Q3 2022, reducing batch rejections.","CEO Hugh O'Dowd says approval enables scaling production to meet increasing customer demand for procedure-free birth control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378484,"accession_number":"0001564590-22-020389","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TherapeuticsMD Q1 net loss $49M on flat revenue; completes $150M vitaCare sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $19.3M, down slightly from $19.6M Q1 2021.","Net loss $49.0M ($5.69 per share) vs $39.4M loss year ago; includes $8.4M debt extinguishment loss.","Cash $30.4M at March 31, down from $65.1M Dec 2021; used $120M vitaCare proceeds to reduce debt.","ANNOVERA prescriptions up 27% YoY to 8,014; new prescribers up 16% YoY.","Completed $150M divestiture of vitaCare in five weeks; $16M PIK fee waived."],"consensus_eps_estimate":0.0612,"consensus_eps_actual":-5.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":19333000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378483,"accession_number":"0001564590-22-018687","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["5.03","3.03","9.01"],"status":"ready","headline":"TherapeuticsMD effects 1-for-50 reverse stock split; authorized shares cut to 12M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective May 6, 2022; every 50 shares become 1 share.","Authorized shares reduced from 600M to 12M; fractional shares rounded up.","Trading on split-adjusted basis under TXMD begins May 9, 2022.","No stockholder approval required under Nevada law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378482,"accession_number":"0001564590-22-016083","cik":25743,"company_name":"TherapeuticsMD, Inc.","ticker":"TXMD","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"TherapeuticsMD announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approves 1-for-50 reverse stock split to cure Nasdaq minimum bid price non-compliance.","Effective May 6, 2022 at 5:00 p.m. ET; post-split trading on Nasdaq under \"TXMD\" begins May 9, 2022.","No stockholder vote required; fractional shares rounded up to nearest whole share.","Nasdaq granted extension to June 1, 2022 to regain compliance with $1.00 bid price.","Authorized shares reduced from 600 million to 12 million; authorized reduction matches split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23958929.51658768,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-04-27T23:59:59+00:00|378482"}